{
 "id": "1102916",
 "text": "Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. ==Overview== The Vertex Pharmaceuticals was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. Its headquarters are in South Boston, Massachusetts. It has three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England. ==History== ===1980s=== The Vertex Pharmaceuticals was founded in 1989 by Joshua Boger and Kevin J. Kinsella . to \"transform the way serious diseases are treated.\" ===1990s=== Barry Werth described the company in his 1994 book, The Billion-Dollar Molecule. His 2014 book, The Antidote: Inside the World of New Pharma, described the company's development over the next20 years. ===2000s=== By 2004, its products were mostly made for treating viral infections, inflammatory and autoimmune disorders, and cancer. In 2009, the company had about 1,800 employees, including 1,200 in the Boston area. ===2010s=== In 2014, it sold the rights to the royalties of the drugs for $3.3 billion. The drug, Trikafta, could extend the lives of some young patients by up to 45 years. In the US, it costs $300,000 per patient, per year. Because it is so expensive only 12% of people in the world with Cystic fibrosis get it. It has a new painkiller drug which is not dangerous. It plans to market it and replace the opioid painkillers which have killed many people in the USA. By 2019, there were about 2,500 employees. The Cystic Fibrosis Foundation invested $150 million in the company to encourage development of drugs for Cystic fibrosis. In 2019, the company made $4.2 billion. ===2020s=== In 2023, it made $9.9 billion. ==References== Category:Companies based in Boston Category:1989 establishments in the United States Category:Pharmaceutical companies of the United States",
 "title": "Vertex Pharmaceuticals"
}